Literature DB >> 27344167

Local and systemic renin-angiotensin system participates in cardiopulmonary-renal interactions in monocrotaline-induced pulmonary hypertension in the rat.

Eva Malikova1, Kristina Galkova1, Peter Vavrinec1, Diana Vavrincova-Yaghi1, Zuzana Kmecova1, Peter Krenek2, Jan Klimas1.   

Abstract

Renin-angiotensin system (RAS) is one of the pathophysiological mechanisms in heart failure. Recently, involvement of the kidney in the disease progression has been proposed in patients with pulmonary arterial hypertension (PAH). We hypothesized that local and systemic RAS could be the central regulators of cardiopulmonary-renal interactions in experimental monocrotaline-induced pulmonary hypertension (PH) in rats. Male 12-week-old Wistar rats were injected subcutaneously with monocrotaline (60 mg/kg). The experiment was terminated 4 weeks after monocrotaline administration. Using RT-PCR, we measured the expression of RAS-related genes in right and left ventricles, lungs and kidneys, together with indicators of renal dysfunction and damage. We observed a significantly elevated expression of angiotensin-converting enzyme (ACE) in both left and right ventricles and kidneys (P < 0.05), but a significantly decreased ACE in the lungs (P < 0.05). Kidneys showed a significant 2.5-fold increase in renin mRNA (P < 0.05) along with erythropoietin, TGFβ1, COX-2, NOS-1 and nephrin. Expression of erythropoietin correlated inversely with hemoglobin oxygen saturation and positively with renin expression. In conclusion, monocrotaline-induced PH exhibited similar alterations of ACE expression in the left and right ventricles, and in the kidney, in contrast to the lungs. Increased renal renin was likely a consequence of renal hypoxia/hypoperfusion, as was increased renal erythropoietin expression. Alterations in RAS in the monocrotaline model are probably a result of hypoxic state, and while they could serve as a compensatory mechanism at a late stage of the disease, they could be viewed also as an indicator of multiorgan failure in PAH.

Entities:  

Keywords:  Angiotensin-converting enzyme; Erythropoietin; Kidney; Monocrotaline; Pulmonary hypertension; Renin–angiotensin system

Mesh:

Substances:

Year:  2016        PMID: 27344167     DOI: 10.1007/s11010-016-2740-z

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  60 in total

1.  Right ventricular angiotensin converting enzyme activity and expression is increased during hypoxic pulmonary hypertension.

Authors:  N W Morrell; S M Danilov; K B Satyan; K G Morris; K R Stenmark
Journal:  Cardiovasc Res       Date:  1997-05       Impact factor: 10.787

Review 2.  Cardio-Pulmonary-Renal Interactions: A Multidisciplinary Approach.

Authors:  Faeq Husain-Syed; Peter A McCullough; Horst-Walter Birk; Matthias Renker; Alessandra Brocca; Werner Seeger; Claudio Ronco
Journal:  J Am Coll Cardiol       Date:  2015-06-09       Impact factor: 24.094

3.  Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet.

Authors:  P Harding; D H Sigmon; M E Alfie; P L Huang; M C Fishman; W H Beierwaltes; O A Carretero
Journal:  Hypertension       Date:  1997-01       Impact factor: 10.190

4.  ACE2-angiotensin-(1-7)-Mas axis might be a promising therapeutic target for pulmonary arterial hypertension.

Authors:  Hailong Dai; Lihong Jiang; Zhicheng Xiao; Xuefeng Guang
Journal:  Nat Rev Cardiol       Date:  2015-05-05       Impact factor: 32.419

Review 5.  The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.

Authors:  Giuseppe Remuzzi; Norberto Perico; Manuel Macia; Piero Ruggenenti
Journal:  Kidney Int Suppl       Date:  2005-12       Impact factor: 10.545

6.  Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway.

Authors:  J Gossmann; R Burkhardt; S Harder; T Lenz; A Sedlmeyer; U Klinkhardt; H Geiger; E H Scheuermann
Journal:  Kidney Int       Date:  2001-07       Impact factor: 10.612

7.  Role of neuronal nitric oxide synthase (NOS1) in the pathogenesis of renal hemodynamic changes in diabetes.

Authors:  R Komers; J N Lindsley; T T Oyama; K M Allison; S Anderson
Journal:  Am J Physiol Renal Physiol       Date:  2000-09

8.  Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.

Authors:  Bradley A Maron; Ying-Yi Zhang; Kevin White; Stephen Y Chan; Diane E Handy; Christopher E Mahoney; Joseph Loscalzo; Jane A Leopold
Journal:  Circulation       Date:  2012-07-11       Impact factor: 29.690

9.  Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice.

Authors:  Kimio Satoh; Yutaka Kagaya; Makoto Nakano; Yoshitaka Ito; Jun Ohta; Hiroko Tada; Akihiko Karibe; Naoko Minegishi; Norio Suzuki; Masayuki Yamamoto; Masao Ono; Jun Watanabe; Kunio Shirato; Naoto Ishii; Kazuo Sugamura; Hiroaki Shimokawa
Journal:  Circulation       Date:  2006-03-13       Impact factor: 29.690

10.  Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure.

Authors:  Peter van der Meer; Adriaan A Voors; Erik Lipsic; Tom D J Smilde; Wiek H van Gilst; Dirk J van Veldhuisen
Journal:  J Am Coll Cardiol       Date:  2004-07-07       Impact factor: 24.094

View more
  4 in total

Review 1.  Alternative RAS in Various Hypoxic Conditions: From Myocardial Infarction to COVID-19.

Authors:  Tomas Rajtik; Peter Galis; Linda Bartosova; Ludovit Paulis; Eva Goncalvesova; Jan Klimas
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

2.  Analysis of necroptosis and its association with pyroptosis in organ damage in experimental pulmonary arterial hypertension.

Authors:  Izabela Jarabicová; Csaba Horváth; Eva Veľasová; Lenka Bies Piváčková; Jana Vetešková; Ján Klimas; Peter Křenek; Adriana Adameová
Journal:  J Cell Mol Med       Date:  2022-04-07       Impact factor: 5.295

3.  Experimental animal models of pulmonary hypertension: Development and challenges.

Authors:  Xiao-Han Wu; Jie-Ling Ma; Dong Ding; Yue-Jiao Ma; Yun-Peng Wei; Zhi-Cheng Jing
Journal:  Animal Model Exp Med       Date:  2022-03-25

4.  Disease severity-related alterations of cardiac microRNAs in experimental pulmonary hypertension.

Authors:  Zuzana Kmecova; Jana Veteskova; Katarina Lelkova-Zirova; Lenka Bies Pivackova; Gabriel Doka; Eva Malikova; Ludovit Paulis; Peter Krenek; Jan Klimas
Journal:  J Cell Mol Med       Date:  2020-05-12       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.